The RiverMend Health Website - RiverMend Health is a premier provider of evidence-based, scientifically driven addiction medicine delivering world-class treatment through our nationwide network of leading addiction recovery experts and treatment centers...
The Substance Abuse and Mental Health Services Administration (SAMHSA) is the agency within the U.S. Department of Health and Human Services that leads public health efforts to advance the behavioral health of the nation. SAMHSA's mission is to reduce the impact of substance abuse and mental illness on America's communities.
A groundbreaking study from The University of Texas at Arlington has revealed a disturbing reality: one in four American adolescents is exposed to violence in their neighbourhood. Moreover, these young people are more than twice as likely to turn to cigarettes, alcohol, or drugs as a coping mechanism. This pattern of teen substance use represents a critical public health challenge that demands immediate attention.
The research, published in the Journal of Affective Disorders, analysed responses from 20,005 adolescents aged 12 to 18 using data from the 2023 Youth Risk Behaviour Survey. Furthermore, the findings shed light on alarming patterns connecting environmental trauma to risky behaviours.
How Neighbourhood Violence Fuels Teen Substance Use
Professor Philip Baiden led the study at UT Arlington’s School of Social Work. He emphasised that violence is far from rare in young people’s lives. “Youth exposed to neighbourhood violence often carry the psychological weight of chronic stress, fear, and trauma,” Dr Baiden explained. Consequently, many turn to alcohol, marijuana, vaping, or other substances to self-medicate or numb the emotional impact.
The study examined five categories: cigarette smoking, alcohol consumption, electronic vaping products, marijuana use, and prescription opioid misuse. Notably, exposure to neighbourhood violence was associated with higher odds of using all five substances. Additionally, researchers controlled for demographics, mental health symptoms, physical activity, and bullying involvement.
Youth Drug Abuse Reaches Crisis Levels
According to the 2024 National Institute on Drug Abuse annual report, 58.3% of individuals aged 12 or older reported using tobacco, vaping nicotine, alcohol, or an illicit drug in the prior month. This widespread youth drug abuse contributes to preventable illness and death across the nation.
Dr Catherine LaBrenz is the study co-author and associate professor at UTA’s School of Social Work. She noted that previous research has shown neighbourhood violence can fundamentally alter how the brain processes emotions. “When teens experience chronic fear or trauma, it can increase vulnerability to substance use,” she said.
Cyberbullying Drives Adolescent Drug Abuse
The research uncovered several surprising patterns beyond neighbourhood violence. Indeed, cyberbullying emerged as more strongly linked to adolescent substance use than traditional school bullying. This finding carries profound implications for prevention strategies.
“Cyberbullying is distinct in that it follows adolescents everywhere,” Baiden explained. “There is no escape. When it is cyberbullying, it spreads widely and persists indefinitely. You don’t know who has access to it, which makes its emotional impact even more traumatic. You can’t just delete it.”
The Sports Paradox
In a nuanced finding, the study identified that students participating in team sports tend to report higher rates of alcohol use. Team sports offer structure, belonging, and social support. However, they also expose adolescents to peer cultures where drinking may be normalised.
“That helps explain why we see increased odds of drinking amongst youth who participate,” Baiden noted.
Pathways to Prevention
The researchers emphasise that documenting these adverse effects is only the beginning. Therefore, the team plans to focus future research on identifying specific interventions. Counsellors, mental health professionals, and social workers can implement these when working with youth who experience neighbourhood violence.
Understanding the connection between environmental trauma and teen substance use represents a crucial step towards developing targeted prevention programmes. By addressing the root causes rather than simply treating the symptoms, communities can better support vulnerable adolescents.
The study’s findings highlight the urgent need for comprehensive approaches. These must consider young people’s lived experiences, including exposure to violence, online harassment, and peer influence. Consequently, only through such holistic understanding can effective strategies emerge to protect adolescents from the devastating cycle of trauma and substance misuse.
Statistics tell a sobering story. With one in four teens exposed to violence and 58.3% of young people aged 12 or older using substances, the scale of this crisis cannot be ignored. Nevertheless, armed with this research, communities now have a clearer roadmap for intervention.
UTA Social Work professors Angela J. Hall and Joshua Awua were contributing authors to the study.
(This is just another outcome of Harm Reduction Only Ideology – The ever-increasing permission models that enable and EQUIP (like Needle Distribution Programs) ongoing drug use isn’t seeing drug use and its intensity reducing, only increasing. This is not only bad policy practice, it is contrary to all the aims of national and international drug policy intents – Welcome to drug use normalisation 101)
A recent national study has revealed serious health consequences tied to a practice many people underestimate. The National Drug and Alcohol Research Centre at UNSW Sydney published the research in January 2026. It examined the co-injection of drugs among people who regularly inject substances across Australia. The findings show just how widespread this behaviour has become, and who faces the greatest risk.
What Is Co-Injection of Drugs?
Co-injection means mixing two or more drugs inside a single syringe before injecting them. This differs from using multiple substances on the same day. With co-injection, the body receives everything at once, in the same dose. That simultaneous intake puts the body under serious pressure. It must process several substances at the same time, with no ability to manage the combined effects.
The 2025 Illicit Drug Reporting System (IDRS) surveyed 865 people across all Australian capital cities. The study found that 18% of participants had combined two or more drugs in the same syringe within the month before their interview. Most of them did this more than once. For a significant number of people, co-injection is not a one-off event but a repeated pattern.
The Most Common Drug Combinations
Among those combining drugs in the same syringe, the top combination was methamphetamine crystal mixed with heroin. This makes sense given the data. Opioids and stimulants already rank as the two most commonly injected drug classes in Australia. Research from Melbourne between 2017 and 2019 confirmed a similar trend. Studies in Seattle also recorded a sharp rise in the co-use of methamphetamine and opioids over the same period.
The data also picked up diphenhydramine, an antihistamine with sedative effects sometimes found in over-the-counter sleep capsules. GHB, ketamine, and various pharmaceutical stimulants showed up as well. Of those who combined drugs in the same syringe, 84% mixed two substances. Around 13% used three drugs at once.
Who Is Most Likely to Co-Inject?
The study linked several factors to a higher likelihood of co-injection of drugs. Men reported this practice at notably higher rates. Daily injectors stood out too. They held roughly four times the odds of combining substances in a single syringe compared to those who injected less often.
Needle sharing played a significant role as well. People who shared syringes in the past month were more than twice as likely to have co-injected. Researchers also identified “bingeing” as a key risk factor. Bingeing means using drugs continuously for 48 hours or more without sleep. Those who had binged were around four times more likely to combine substances in one syringe. Together, these patterns show that co-injection tends to cluster among people with the most intense and high-risk drug use habits.
Why Co-Injection of Drugs Is So Dangerous
Mixing stimulants and opioids in the same syringe puts major strain on the cardiovascular and respiratory systems. When someone takes two substances at different times, the body can begin to clear one before the other arrives. Co-injection removes that buffer entirely. A stimulant pushes the heart rate up and sharpens alertness. At the same time, an opioid suppresses breathing and slows the central nervous system. That direct conflict between the two substances makes certain combinations deeply unpredictable and potentially fatal.
Earlier studies connected the co-injection of methamphetamine and opioids to poorer physical and mental health outcomes over time. They also flagged an elevated risk of overdose. The 2025 IDRS data tell a similar story. The behaviour clusters tightly around other high-risk patterns, especially daily use and binge episodes. Both of those patterns carry their own serious long-term health consequences.
Understanding the Bigger Picture
Co-injection of drugs is not a fringe activity. A meaningful number of regular injectors in Australia engage in it. It tends to happen among people whose drug use is already the most intense. The mix of stimulants and opioids in a single syringe represents one of the more dangerous forms of polydrug use seen in the country today. The health consequences, both immediate and long-term, need far greater public awareness.
Drug use patterns keep shifting across Australia. The risks tied to co-injection of drugs will stay relevant as long as that shift continues. Understanding exactly what people put into their bodies, and how, stays critical. The 2025 IDRS data give us a national snapshot. It is both timely and relevant, not only for researchers and clinicians, but for anyone who cares about public health.
A fentanyl vaccine will enter human trials in early 2026, offering a revolutionary approach to preventing drug use before it starts. Developed with support from the US Department of Defence and licensed by ARMR Sciences, the experimental treatment could become the first true biological deterrent against opioid use by making the drug completely ineffective.
The fentanyl vaccine trials will begin recruiting patients in the Netherlands, likely in January or February 2026. Animal studies showed the treatment completely eliminates fentanyl’s effects, removing any reason to use the drug in the first place.
Making Drug Use Pointless
Unlike existing approaches that manage addiction after it develops, this anti-fentanyl immunisation operates on a simple principle: if the drug doesn’t work, why would anyone bother taking it? “Our goal as a company is to eliminate the lethality of drugs on the market,” said Colin Gage, co-founder and chief executive of ARMR Sciences. “We want to do this by attacking the root cause not just of addiction, but obviously of overdose as well.”
The vaccine doesn’t just prevent death. It prevents the euphoria, the high, the entire point of using fentanyl. This represents a fundamental shift from managing consequences to eliminating motivation.
The Brutal Reality of Fentanyl
Fentanyl stands as a synthetic opioid approximately 50 times more potent than heroin. A dose of just 2 milligrams, equivalent to approximately 12 grains of salt, can prove deadly according to the US Drug Enforcement Administration.
Provisional data shows over 48,000 people died from opioid overdoses in the United States during 2024 alone. Thousands more became addicted, their lives derailed by a substance they often encountered unknowingly in contaminated street drugs.
The crisis demands a solution that prevents people from wanting to use these substances at all.
How the Fentanyl Vaccine Trials Will Work
The vaccine operates in the circulatory system, intercepting fentanyl before it reaches the brain. This represents the first treatment that doesn’t act on opioid receptors themselves but instead neutralises the drug entirely.
Because fentanyl molecules are too small to trigger natural immune responses, researchers attached them to other substances. The team, led by Colin Haile from the University of Houston and ARMR co-founder, selected an inactivated diphtheria toxin called CRM197, already used in existing vaccines.
To amplify the effect, researchers added dmLT, a compound obtained from modified bacteria. These components attach to a synthetic part of the fentanyl molecule.
Following vaccination, the immune system produces antibodies that bind to fentanyl, preventing it from crossing the blood-brain barrier. The drug gets eliminated from the body without ever producing euphoria, pain relief, or any rewarding sensation.
In rat studies, the anti-fentanyl immunisation blocked fentanyl from entering the brain completely. The rats showed no signs of euphoria, no behavioural changes, nothing. The drug simply didn’t work.
No High, No Point
This is the crucial deterrent effect. The vaccine doesn’t make fentanyl slightly less effective or reduce the high. It eliminates the high entirely.
“We’re targeting people who want to quit using,” Haile said. “The vaccine gives them the chance to understand they won’t get the desired effect anymore and that there’s no point in consuming the drug.”
For someone considering trying fentanyl, the vaccine removes any potential appeal. Why experiment with a deadly substance if you know it won’t produce any effect? The risk-reward calculation becomes absurd: all risk, zero reward.
For young people facing peer pressure or curiosity about drugs, the vaccine provides a biological shield. Even if they make a poor decision, the drug won’t work. They won’t experience the euphoria that drives continued use. The addiction cycle never begins because the initial reward never occurs.
Preventing the First Use
Traditional approaches focus on treating addiction after it develops. Education programmes warn about dangers but rely on people making good decisions under pressure. Treatment facilities help those already struggling but can’t reach people before they start using.
The anti-fentanyl immunisation changes this equation entirely. It prevents the drug from working at the biological level. Decision-making, peer pressure, moment of weakness—none of it matters if the drug produces no effect.
This represents true prevention. Not managing risk, not treating consequences, but stopping the problem before it starts.
The vaccine requires an initial dose followed by boosters at three and six weeks. Animal studies showed complete blockage of fentanyl effects six months after initial vaccination.
“The longest interval we’ve monitored animals was approximately six months, and we observed complete blocking of fentanyl effects,” Haile explained.
The 2026 Testing Protocol
The Phase I fentanyl vaccine trials scheduled for early 2026 will include 40 participants. The primary focus involves vaccine safety and potential adverse effects. Researchers will also monitor production of anti-fentanyl antibodies.
Success in this phase leads to Phase II studies testing vaccine efficacy. Some participants will receive safe doses of medical-grade fentanyl under strict supervision to verify the vaccine maintains its protective effect. The expectation: the drug will produce absolutely no response.
Both dmLT and CRM197 components have been tested in humans as parts of other vaccines. This provides safety reassurance as the treatment moves towards human trials.
Eliminating Temptation
In theory, someone could consume massive quantities of fentanyl to overwhelm the antibodies. However, researchers believe the absence of any euphoric effect will completely discourage this behaviour.
Think about it practically. If you take a drug and feel nothing—no high, no euphoria, no sensation whatsoever—why would you take more? The entire point of drug use disappears.
This isn’t willpower or self-control. It’s biology. The brain’s reward system never activates. The addiction pathway never forms. The behaviour has no reinforcement.
For parents worried about their children, for schools concerned about students, for communities devastated by drug deaths, this offers something unprecedented: a way to make the drug genuinely unappealing by making it genuinely useless.
Who Should Receive the Vaccine
The anti-fentanyl immunisation could serve young people before they ever encounter these substances. Vaccinating teenagers removes the possibility of fentanyl producing rewarding effects during vulnerable years when peer pressure peaks and decision-making remains immature.
People with family histories of substance use could receive protection before genetic vulnerability combines with environmental exposure. The vaccine breaks the intergenerational cycle by preventing the drug from working even if someone tries it.
Communities experiencing drug crises could offer widespread vaccination, creating a population where fentanyl simply doesn’t function. When enough people are vaccinated, the social dynamics around drug use shift. If your peers tell you the drug doesn’t work, experimentation loses its appeal.
“I lost two close childhood friends to fentanyl overdose,” Gage said, highlighting the personal stakes driving this research.
His friends likely didn’t set out to become addicted. They probably didn’t intend to die. They made decisions that spiralled into tragedy. The vaccine could prevent those spirals by preventing the initial effect that starts them.
Legitimate Medical Use
Fentanyl has legitimate medical applications, particularly as an analgesic in emergency situations. The vaccine’s specificity addresses this concern.
According to researchers, antibodies produced by the vaccine don’t bind to other opioids such as morphine, oxycodone, or methadone. Medical professionals retain options for managing severe pain whilst the vaccine protects against illicit fentanyl.
The treatment targets the specific threat whilst preserving medical tools. This specificity makes widespread vaccination practical.
A New Prevention Paradigm
Research shows both the general public and people directly affected by drug crises view an anti-fentanyl vaccine positively. The concept resonates: why not prevent drug use by making drugs ineffective?
This approach sidesteps debates about willpower, moral failing, or personal responsibility. It doesn’t matter why someone tries fentanyl if the drug produces no effect. The biological reality supersedes the psychological complexity.
For schools, this could become part of standard vaccination schedules. For communities, it could be offered alongside other public health interventions. For families, it provides peace of mind that even poor decisions won’t lead to addiction or death.
The fentanyl vaccine trials launching in 2026 represent a fundamentally different approach. Not managing addiction, not treating overdoses, not counselling users but preventing the entire problem by eliminating the drug’s appeal at the most basic level.
Changing the Calculation
Young people face constant messages about drugs. Media glamorises substance use. Peers experiment and report effects. Curiosity combines with adolescent risk-taking. Traditional prevention relies on education and fear, hoping young people make good decisions.
The vaccine changes this calculation entirely. It doesn’t ask teenagers to resist temptation through willpower. It removes the temptation by removing the reward.
Imagine telling young people: “You’re vaccinated. Even if you try fentanyl, nothing will happen. No high, no euphoria, nothing. It would be like taking a sugar pill, except dangerous and pointless.”
This message resonates differently than “just say no.” It’s not about being strong or making good choices. It’s about biological reality. The drug won’t work. Period.
What Happens Next
If approved following successful fentanyl vaccine trials, this would become an unprecedented tool in preventing drug use. Success would validate a completely new paradigm in substance abuse prevention.
Instead of focusing on consequences, society could offer protection before experimentation begins. Instead of treating addiction, we could prevent it by making the drug ineffective. Instead of hoping people resist temptation, we could eliminate the reward that creates temptation.
The vaccine doesn’t replace drug education. Young people still need to understand dangers. However, it provides a biological backstop. Even if education fails, even if someone makes a poor decision, the drug won’t work.
For families, this offers genuine hope. Not hope that loved ones will make good decisions under pressure. Hope that even bad decisions won’t lead to addiction because the drug simply won’t function.
For communities ravaged by opioid crises, it offers a path forward. Widespread vaccination could create a population where fentanyl loses its market. If the drug doesn’t produce effects, dealers can’t sell it. The economic model of drug trafficking collapses.
The Stakes in 2026
The anti-fentanyl immunisation entering trials in 2026 represents years of research finally reaching human testing. The approach is radical: don’t manage drug use, prevent it by making drugs useless.
With over 48,000 American deaths from opioid overdoses in 2024 alone, the urgency couldn’t be clearer. Traditional approaches haven’t solved the crisis. Education hasn’t stopped experimentation. Treatment hasn’t prevented deaths.
Perhaps the solution isn’t better education or better treatment. Perhaps it’s making the drug ineffective so there’s no point in using it at all.
The fentanyl vaccine trials beginning in 2026 will test whether this bold approach works in humans as it did in animals. If successful, it could mark a turning point. Not in how we treat addiction, but in how we prevent it from ever beginning.
This commentary argues the need to prioritize regulation and abstinence-based prevention and recovery as critical services in efforts to maximize the reduction of substance-related harm and the promotion of mental health at a population-level.
One of the most difficult subjects to understand and assess in the drug policy and practice field is harm reduction because of disputes about its intent and meaning. Issues 2, 3 and 4 will address the subject in depth with special attention to the history of the concept in a three part series. The Journal of Global Drug Policy and Practice, a joint effort of the Institute on Global Drug Policy and the International Scientific and Medical Forum on Drug Abuse is an international, open access, peer-reviewed, online journal with the goal of bridging the information gap on drug policy issues between the medical/scientific community, policy makers and the concerned lay public.
World Federation Against Drugs (W.F.A.D) Dalgarno Institute is a member of this global initiative. For evidence based data on best practice drug policy in the global context.
The Institute for Behavior and Health, Inc. is to reduce the use of illegal drugs. We work to achieve this mission by conducting research, promoting ideas that are affordable and scalable...
Drug Free Australia Website. Drug Free Australia is a peak body, representing organizations and individuals who value the health and wellbeing of our nation...
(I.T.F.S.D.P) This international peak body continues to monitor and influence illicit drug policy on the international stage. Dalgarno Institute is a member organisation.
The National Alliance for Action on Alcohol is a national coalition of health and community organisations from across Australia that has been formed with the goal of reducing alcohol-related harm.
RiverMend Health is a premier provider of scientifically driven, specialty behavioral health services to those suffering from alcohol and drug dependency, dual disorders, eating disorders, obesity and chronic pain.
A groundbreaking study from The University of Texas at Arlington has revealed a disturbing reality: one in four American adolescents is exposed to violence in their neighbourhood. Moreover, these young people are more than twice as likely to turn to cigarettes, alcohol, or drugs as a coping mechanism. This pattern of teen substance use represents a critical public health challenge that demands immediate attention.
A recent national study has revealed serious health consequences tied to a practice many people underestimate. The National Drug and Alcohol Research Centre at UNSW Sydney published the research in January 2026. It examined the co-injection of drugs among people who regularly inject substances across Australia. The findings show just how widespread this behaviour has become, and who faces the greatest risk.
Fentanyl stands as a synthetic opioid approximately 50 times more potent than heroin. A dose of just 2 milligrams, equivalent to approximately 12 grains of salt, can prove deadly according to the US Drug Enforcement Administration.
Prioritizing Abstinence-Based Prevention, Regulation, and Recovery to Reduce Substance-Related Harm and Promote Mental Health at a Population-Level
